Marie L. de Bruin

Pharmacology, Toxicology and PharmaceuticsEconomics, Econometrics and FinanceBiochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 2 papers. Top paper: “EU decision-making for marketing authorization of advanced therapy medicinal products: a case study”.

EU decision-making for marketing authorization of advanced therapy medicinal products: a case study

Drug Discovery Today(2018)10.1016/j.drudis.2018.03.008

N/A

2.1DataRank · unranked

36 citations

Delphi G.M. Coppens, Jarno Hoekman, Marie L. de Bruin, Hubert G.M. Leufkens, Henk-Jan Guchelaar +2 more

Regulatory, health technology assessment and company interactions: the current landscape and future ecosystem for drug development, review and reimbursement

International Journal of Technology Assessment in Health Care(2023)10.1017/s0266462323000144

N/A

0DataRank · unranked

13 citations

Neil McAuslane, Wim Goettsch, Hubert G. M. Leufkens, Marie L. de Bruin, Ting Wang